Continuous high-titer HIV-1 vector production

Y Ikeda, Y Takeuchi, F Martin, FL Cosset… - Nature …, 2003 - nature.com
Y Ikeda, Y Takeuchi, F Martin, FL Cosset, K Mitrophanous, M Collins
Nature biotechnology, 2003nature.com
Human immunodeficiency virus type 1 (HIV-1)–based vectors are currently made by
transient transfection, or using packaging cell lines in which expression of HIV-1 Gag and
Pol proteins is induced,,. Continuous vector production by cells in which HIV-1 Gag-Pol is
stably expressed would allow rapid and reproducible generation of large vector batches.
However, attempts to make stable HIV-1 packaging cells by transfection of plasmids
encoding HIV-1 Gag-Pol have resulted in cells which secrete only low levels of p24 antigen …
Abstract
Human immunodeficiency virus type 1 (HIV-1)–based vectors are currently made by transient transfection, or using packaging cell lines in which expression of HIV-1 Gag and Pol proteins is induced,,. Continuous vector production by cells in which HIV-1 Gag-Pol is stably expressed would allow rapid and reproducible generation of large vector batches. However, attempts to make stable HIV-1 packaging cells by transfection of plasmids encoding HIV-1 Gag-Pol have resulted in cells which secrete only low levels of p24 antigen (20–80 ng/ml),,, possibly because of the cytotoxicity of HIV-1 protease. Infection of cells with HIV-1 can result in stable virus production; cell clones that produce up to 1,000 ng/ml secreted p24 antigen have been described. Here we report that expression of HIV-1 Gag-Pol by a murine leukemia virus (MLV) vector allows constitutive, long-term, high-level (up to 850 ng/ml p24) expression of HIV-1 Gag. Stable packaging cells were constructed using codon-optimized HIV-1 Gag-Pol and envelope proteins of gammaretroviruses; these producer cells could make up to 107 293T infectious units (i.u.)/ml (20 293T i.u./cell/day) for at least three months in culture.
nature.com